{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.64","upperLimit":"8.19","value":"5.89"},{"groupId":"OG001","lowerLimit":"1.12","upperLimit":"12.89","value":"2.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Duration of time from the start of treatment to time of death due to any causes. Patients who did not die were censored on their last known alive date. Kaplan-Meier methods will be used and the median and 95% confidence intervals will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab Vedotin 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Negative/Unknown cohort.","id":"OG000","title":"CD30 Negative/Unknown"},{"description":"Brentuximab Vedotin 1.8 mg/ kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Positive cohort.","id":"OG001","title":"CD30 Positive"}],"paramType":"MEDIAN","populationDescription":"All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}